Targeted and Syndromic Molecular Diagnostics Testing from Luminex®

Request A Quote
Request a demo

TECHNOPATH partner with Luminex® Corporation to offer a comprehensive range of molecular assays for respiratory, gastrointestinal and bloodstream testing, in addition to womens’ health.
Luminex® is the only molecular diagnostics developer providing both targeted and syndromic clinical tests for infectious diseases — so you never have to compromise on diagnostic performance, cost, or turnaround time to generate results.

From low-volume microbiology labs to high-capacity reference labs and everything in between, Luminex® offers flexible solutions to meet the clinical, operational, and economical needs of your healthcare system.

Molecular SARS-CoV-2 Testing Solutions
The NxTAG® Respiratory Pathogen Panel + SARS-CoV-2 (NxTAG® RPP + SARS-CoV-2) is a qualitative test for the detection of nucleic acids from multiple respiratory viruses and bacteria in nasopharyngeal swabs, oropharyngeal swabs, nasal swabs, anterior nasal swabs, mid-turbinate nasal swabs, nasal aspirates, and nasal washes. This assay is designed for use on the MAGPIX® System. Comprehensive Panel: Detects 20 viral pathogens, including SARS-CoV-2 (ORF1ab and M gene) and 3 bacterial pathogens, in a single well—enabling thorough respiratory health analysis.

For more targeted coronavirus testing in moderate-complexity labs, the ARIES® SARS-CoV-2 Assay is a sample-to-answer test that detects SARS-CoV-2 in nasopharyngeal swabs.

INFECTIOUS DISEASE TESTING OPTIONS

Luminex® offers the most scalable, flexible respiratory infection testing portfolio to assist labs with managing the needs of physicians, patients, and the overall healthcare system. Our molecular diagnostic assays allow you to adjust target selection and sample throughput for maximum testing accuracy, cost efficiency, and clinical impact.

Learn more about our respiratory infection testing options:

From ARIES® C. difficile Assay targeted assays for C. difficile to broad disease state panels covering community-acquired and persistent diarrhoea pathogens, clinical labs need flexibility and scalability in their GI assays to deliver optimal results to physicians for patient care, antimicrobial stewardship, and infection control.

That’s why Luminex® offers targeted diagnostic options for nosocomial diarrhoea and syndromic panels for community acquired/traveler’s diarrhoea that align with recommended guidelines. These molecular solutions offer improved clinical outcomes when compared to traditional culture methods. In addition, the flexibility empowers clinical laboratories to improve efficiency by reducing turnaround time, consolidating sample testing, and reducing opportunities for human error. Overall, these solutions can help clinical labs generate actionable results while reducing costs.

Our gastrointestinal testing platforms are scalable to fit low-volume labs, high-capacity reference labs, and everything in between.

Learn more about our gastrointestinal infection testing options:

The VERIGENE® Bloodstream Infection portfolio empowers laboratories to rapidly identify causative pathogens, as well as their associated resistance markers.

Clinical studies have demonstrated that the VERIGENE® Bloodstream Infection assays lower overall hospital costs, shorten the patient’s length of stay, and most importantly, improve patient outcomes by enabling a more targeted treatment plan—faster. These assays have been proven to synergise with antimicrobial stewardship programs, reduce the use of unnecessary antibiotics, and effectively manage infection control.

VERIGENE® Gram-Positive Blood Culture Nucleic Acid Test (BC-GP)

VERIGENE® Gram-Negative Blood Culture Nucleic Acid Test (BC-GN)

The Luminex® Women’s Health assays, ranging from antenatal testing to sexually transmitted infections, offer highly sensitive, accurate, and easy to use PCR-based options that enable laboratories to provide physicians and patients with precise results.

Our ARIES® assays can be scaled to meet the throughput needs of labs ranging from community hospitals to large reference facilities. These assays are designed to run on ARIES® Systems, which are sample to answer platforms that require minimal hands-on time, and offer the flexibility to run both IVD assays and laboratory developed tests.

Learn more about our women’s health testing options:

ARIES® GBS Assay
ARIES® HSV 1&2 Assay

Integrate and simplify user defined protocols with ARIES® Systems using intuitive software and reagents
ARIES® and ARIES® M1 Systems are crafted to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today’s lean laboratory. ARIES® is an open platform that allows customers to run User Defined Protocols (UDP) and is capable of running both UDP and IVD assays in a single batch, when using a universal assay protocol.

Utilise the full ARIES® tool kit to simplify UDPs, and take advantage of the automation provided with the system.

Our UDP tools include:

We are Here To Help

Our team is on hand to help you find the best solution for you and your team.

Get in touch